Skip to content

Efficacy and safety of remimazolam combined with sevoflurane in general anesthesia maintenance in elderly patients

Effect of remimazolam combined with sevoflurane on quality of recovery in general anesthesia in elderly patients: a randomized control trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065332
Enrollment
Unknown
Registered
2022-11-02
Start date
2023-02-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

quality of recovery in general anesthesia in elderly patients

Interventions

Experimental group1:Remimazolam 0.5-1.0 mg/kg/h was maintained during the operation
Experimental group2:Remimazolam combined with 0.5 MAC sevoflurane was maintained during the operation

Sponsors

Dongguan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subjects have a full understanding of the purpose and significance of this trial, volunteer to participate in this clinical trial, and sign an informed consent; 2. Patients who need general anesthesia for tracheal intubation for elective abdominal surgery; 3. Aged 60-80 years, gender is not limited; 4. ASA I-III.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to benzodiazepines, propofol, opioid and other pharmaceutical ingredients or components that may be used in the research; 2. Those who use of benzodiazepines or opioids within 1 month; 3. Those who have a history of mental illness; 4. Those who have cognitive dysfunction; 5. BMI >= 28 kg/m2; 6. Foreseeable difficult intubation; 7. Bradycardia, heart rate < 55 beats/min; 8. Patients with severe heart, lung, liver, and kidney function abnormalities; 9. Those with a history of allergic diseases, with previous malignant hyperthermia and previous history of epilepsy; 10. Those with fat metabolism disorders; 11. Those with myasthenia gravis; 12. Patients unable to understand written information or informed consent regarding the trial.

Design outcomes

Primary

MeasureTime frame
QoR-15 score on the first postoperative day;

Secondary

MeasureTime frame
QoR-15 score on postoperative day 3;Blood flow dynamics;Anesthesia recovery time;

Countries

China

Contacts

Public ContactXie Haihui

Dongguan People's Hospital

xhh900@163.com+86 137 9058 8393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026